---

Methylene Blue | Ingredient Overview: Pharmacokinetics, Formulations, Human Research Evidence, Safety, and Combinations

Methylene blue, also called methylthioninium chloride, is a synthetic thiazine dye and redox-active medical compound studied in humans for acquired methemoglobinemia, vasodilatory shock, neuropsychiatric research, malaria combination therapy, and colonoscopy visualization rather than as a natural dietary nutrient. (FDA) (EMA)

Methylene blue is best understood as a prescription drug, diagnostic dye, and research compound with several distinct human-study contexts. The strongest evidence applies to regulated medical or diagnostic settings, including FDA-labeled acquired methemoglobinemia treatment, EMA-authorized colonoscopy visualization, and clinical research in vasodilatory shock. (FDA) (EMA) (Review) Evidence is more limited for Cognitive Health and Mental Health because those studies are smaller, often acute, and usually adjunctive rather than large standalone outcome trials. (Research) (Review)

Ingredient Identity

• Official name(s): Methylene blue; methylthioninium chloride. (EMA)
• Synonyms: Methylthioninium chloride, methylene blue trihydrate in some pharmaceutical contexts, and thiazine dye terminology in chemical and medical literature. (FDA)
• Classification: Synthetic thiazine dye and redox-active drug compound. (Review)
• CAS number: 61-73-4 is commonly used for methylene blue. (FDA)
• Endogenous vs exogenous: Methylene blue is exogenous and is not a dietary nutrient or endogenous human metabolite. (Review)

Ingredient Snapshot

• Classification: Methylene blue is a synthetic redox-active thiazine dye used in medical, diagnostic, and research settings. (Review)
• Endogenous vs exogenous status: It is an exogenous compound rather than a nutrient naturally produced by the body. (Review)
• Primary human research domains: Human studies include Blood Health, Cardiovascular Health, Digestive and Gastrointestinal Health, Infection, Cognitive Health, and Mental Health. (FDA) (Review) (Research) (Review) (Review)
• Common study formats: The evidence base includes randomized trials, crossover studies, pharmacokinetic studies, diagnostic colonoscopy studies, observational ICU studies, and systematic reviews. (Research) (Research) (Research) (Review)
• Pharmacokinetic characterization status: Human pharmacokinetic work has evaluated oral absorption, bioavailability, metabolism, excretion, blood-cell partitioning, and route-dependent distribution. (Research) (Research) (Research) (FDA)
• Regulatory context (U.S./EU): In the United States, FDA labeling identifies methylene blue injection as a prescription drug for acquired methemoglobinemia. (FDA) In the European Union, EMA identifies methylthioninium chloride in Lumeblue as a prescription diagnostic dye for enhancing visualization of colorectal lesions in adults undergoing screening or surveillance colonoscopy. (EMA)
• Evidence maturity: Evidence is strongest in regulated medical or diagnostic contexts and less mature for broad Cognitive Health or Mental Health claims. (FDA) (Research) (Research)

Introduction

Methylene blue is a synthetic blue dye that can accept and donate electrons, which is why it is described as redox-active. (Review) It does not occur naturally as a food nutrient and is better understood as a drug, diagnostic dye, and biomedical research compound than as a conventional dietary ingredient. (FDA)

People often look up methylene blue because it appears in discussions about mitochondria, cognition, mood, oxygen-related blood chemistry, and blood-vessel tone. Human research has examined several separate contexts, including neuroimaging in healthy adults, bipolar disorder, fear-extinction learning, septic shock, malaria, and diagnostic colonoscopy. (Research) (Research) (Research) (Review) (Research)

This article is informational only, describes methylene blue as a biochemical and medical substance studied in human research, and does not provide medical or dosing advice. (FDA)

Quick Summary

• Methylene blue is a synthetic redox-active thiazine dye used as a drug, diagnostic dye, and research compound rather than as a natural dietary nutrient. (Review) (FDA)
• The strongest human evidence is in regulated medical or diagnostic settings, including acquired methemoglobinemia treatment, colonoscopy visualization, and vasodilatory shock research. (FDA) (Research) (Review)
• Cognitive Health studies have reported acute neuroimaging and memory-related effects, including assessment about 1 hour after oral administration, but the studies are small and short-term. (Research) (Research)
• Mental Health research includes bipolar disorder, fear-extinction, and PTSD exposure-augmentation studies, but these are specialized adjunctive studies rather than evidence for general psychiatric self-use. (Research) (Research) (Review)
• Infection studies have examined methylene blue mostly in malaria combination therapy and transmission-blocking research, not as a broad standalone antimicrobial ingredient. (Review) (Research)
• Human study exposures range from 15 mg/day oral comparator phases to 195–300 mg/day psychiatric-study exposures, 100–200 mg colon-targeted MMX diagnostic tablets, and weight-based IV critical-care protocols. (Research) (Research) (Research) (FDA)
• FDA labeling warns about serious serotonin-syndrome risk with serotonergic drugs and lists G6PD deficiency as a contraindication because of hemolytic-anemia risk. (FDA) (FDA)

Human Research Findings by Condition

Cognitive Health

Human research on Cognitive Health has included small randomized neuroimaging studies in healthy adults. These studies reported acute brain-activity, connectivity, and memory-related signals, but they do not establish long-term cognitive benefit or a general cognitive-use dose. (Research) (Research)

Key human study

Dose studied: Low-dose oral methylene blue; single acute exposure
Population: 26 healthy adults, ages 22–62
Duration: Acute assessment before and about 1 hour after administration

Researchers used functional MRI to examine attention and memory-related brain activity after methylene blue exposure. The study reported increased task-related brain activity and a higher percentage of correct responses during memory retrieval. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: Low-dose oral methylene blue; acute neuroimaging protocol
Population: Healthy adults
Duration: Acute post-administration neuroimaging assessment

A related randomized neuroimaging study examined task-related and resting-state brain connectivity. The study reported that methylene blue modulated functional brain networks, but it did not establish long-term cognitive benefit. (Research)

Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)

Mental Health

Mental Health studies have examined methylene blue mostly as an adjunctive research compound rather than a standalone treatment. Human trials include bipolar disorder studies and exposure-therapy augmentation research, but findings are mixed across outcomes and remain limited by study size, design, and specialized populations. (Research) (Research) (Review)

Key human study

Dose studied: 15 mg/day comparator phase and 195 mg/day active phase
Population: 37 people with bipolar disorder receiving lamotrigine
Duration: 6 months total; two 3-month crossover phases

This randomized crossover study evaluated adjunctive methylene blue for residual symptoms in bipolar disorder. The higher-dose phase was associated with improvement in residual depressive and anxiety symptoms, while cognitive outcomes did not clearly improve. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 15 mg/day and 300 mg/day oral methylene blue
Population: 31 bipolar manic-depressive subjects maintained on lithium
Duration: 2 years

This double-blind crossover trial compared a low-dose and higher-dose year in bipolar manic-depressive illness. Depressive symptoms were reported as less severe during the higher-dose year, while manic symptoms were not significantly different. (Research)

Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 260 mg single post-session oral dose
Population: Adults with marked claustrophobic fear
Duration: Exposure-session intervention with follow-up testing

This randomized trial examined methylene blue after exposure learning. The study reported better retention of fear extinction after successful exposure sessions, but the effect depended on how participants responded during the initial exposure. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)

Cardiovascular Health

Cardiovascular Health evidence focuses mainly on vasodilatory shock, septic shock, and vasoplegic syndrome after cardiac surgery. The human evidence includes randomized trials, observational studies, and meta-analyses, but confidence is limited by small trials, heterogeneous protocols, and critical-care settings. (Research) (Review) (Review)

Key human study

Dose studied: Intravenous methylene blue protocol in septic shock
Population: Adults with septic shock
Duration: ICU treatment period with 28-day outcomes

A randomized clinical trial evaluated early adjunctive methylene blue in septic shock. The trial reported reduced time to vasopressor discontinuation and more vasopressor-free days at 28 days compared with control care. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: 2 mg/kg intravenous bolus followed by stepwise infusions of 0.25, 0.5, 1, and 2 mg/kg/hour
Population: 20 adults with septic shock
Duration: Short-term ICU infusion protocol

This pilot randomized study tested whether methylene blue could counteract vasodilation and reduce adrenergic vasopressor support. The study reported improved vascular tone and reduced adrenergic support during the monitored period. (Research)

Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: Perioperative methylene blue protocol
Population: High-risk cardiac surgery patients
Duration: Perioperative and postoperative follow-up

A randomized trial in high-risk cardiac surgery patients reported that preoperative methylene blue reduced the incidence and severity of vasoplegic syndrome after cardiopulmonary bypass. This evidence belongs to a specialized surgical context and should not be generalized outside monitored care. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Infection

Infection research has examined methylene blue mainly in malaria combination-therapy and transmission-blocking studies. The evidence shows antimalarial and gametocytocidal interest, but it also highlights tolerability, acceptability, formulation, and combination-regimen limitations. (Review) (Research) (Research)

Key human study

Dose studied: 12 mg/kg total over 3 days
Population: Children aged 6–59 months with uncomplicated falciparum malaria
Duration: 3-day treatment regimen with follow-up

This randomized trial tested chloroquine plus methylene blue in young children with uncomplicated falciparum malaria. The regimen was generally tolerated, but efficacy at the studied methylene blue dose was insufficient in that setting. (Research)

Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 36, 54, and 72 mg/kg total doses
Population: Young children with uncomplicated falciparum malaria
Duration: 3-day dose-finding study

This uncontrolled dose-finding study evaluated escalating methylene blue exposure combined with chloroquine. The study helped define tolerability and acceptability issues, including vomiting and discoloration-related concerns, rather than proving standalone efficacy. (Research)

Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)

Additional human study

Dose studied: 15 mg/kg/day for 3 days
Population: G6PD-normal, gametocytaemic male participants aged 5–50 years with asymptomatic P. falciparum infection
Duration: 3-day treatment with transmission assessment

A phase 2 randomized trial examined methylene blue-based therapy for malaria transmission blocking. The study reported reduced transmission potential from humans to mosquitoes in the studied population. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)

Digestive and Gastrointestinal Health

Digestive and Gastrointestinal Health evidence centers on methylene blue as a diagnostic colon-staining agent rather than a digestive supplement. The strongest evidence in this area comes from methylene blue MMX, where MMX refers to a modified-release tablet technology designed to release dye throughout the colon during colonoscopy. (Research) (EMA)

Key human study

Dose studied: 200 mg oral methylene blue MMX
Population: Adults aged 50–75 undergoing screening or surveillance colonoscopy
Duration: Single colonoscopy-preparation context

A phase 3 trial evaluated whether oral methylene blue MMX improved detection of colorectal lesions during colonoscopy. The study reported an 8.5% absolute increase in adenoma detection rate compared with placebo. (Research)

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: 100 mg and 200 mg oral methylene blue MMX
Population: Healthy volunteers undergoing colonoscopy-related staining evaluation
Duration: Single-dose diagnostic study context

A formulation study evaluated modified-release tablets designed to deliver methylene blue to the colon. Both doses produced colonic staining, and the 200 mg dose had favorable staining characteristics in the study. (Research)

Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)

Blood Health

Blood Health is the clearest regulated therapeutic context for methylene blue because FDA labeling identifies methylene blue injection for acquired methemoglobinemia. This is an acute medical-use context requiring diagnosis, IV access, and monitoring, not evidence for routine self-directed oral use. (FDA)

Key human study

Dose studied: FDA-labeled 1 mg/kg IV over 5–30 minutes, with a possible repeat dose 1 hour later in specified circumstances
Population: Pediatric and adult patients with acquired methemoglobinemia
Duration: Acute medical treatment context

FDA labeling describes methylene blue injection as an oxidation-reduction agent for acquired methemoglobinemia. The label reports that, in clinical evidence reviewed for the product, most administered doses were 1 mg/kg, doses ranged from 0.78 to 2 mg/kg, and the recommended dose remains 1 mg/kg. (FDA)

Result: Human studies observed short-term physiological effects
Evidence strength: Strong for regulated indication; not applicable to wellness use
Study source: (FDA)

Dosage & Study Snapshot (Research Context)

Human exposure data for methylene blue come from medical, diagnostic, psychiatric, infectious-disease, ICU, and pharmacokinetic research rather than dietary intake. No dietary intake range applies because methylene blue is not a naturally occurring food nutrient. (Review) The exposure bands below summarize research and medical-study exposures only and should not be interpreted as safe, ideal, or recommended doses. (FDA)

15 mg/day:

The lowest fixed oral exposure in the reviewed human studies is 15 mg/day, used as a low-dose comparator in bipolar disorder research. In the lamotrigine adjunctive crossover study, 15 mg/day was compared with 195 mg/day over two 3-month phases. The lower exposure functioned as a comparator rather than an established therapeutic or wellness dose. The trial reported greater improvement in residual depressive and anxiety symptoms during the higher-dose phase, while cognitive outcomes were not clearly improved. (Research)

Result: Mixed findings
Evidence strength: Limited
Notes / limitations: This comparator dose does not establish a general safe or ideal daily dose.

100 mg single oral dose:

A 100 mg oral methylene blue MMX dose was studied in a colonoscopy-related formulation trial. MMX is a modified-release tablet technology intended to deliver dye through the colon rather than behave like a standard immediate-release oral liquid. The study evaluated staining, pharmacokinetics, and safety in the context of colonoscopy preparation. The dose produced colonic staining, but the study was not designed to evaluate cognition, mood, mitochondrial function, or wellness outcomes. (Research)

Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: This exposure applies to a diagnostic colon-targeted formulation.

195 mg/day:

A 195 mg/day oral exposure was studied as the higher-dose phase in a randomized crossover trial of adjunctive methylene blue in bipolar disorder. The population consisted of adults with bipolar disorder receiving lamotrigine. The study reported improvement in residual depressive and anxiety symptoms during the higher-dose phase compared with the 15 mg/day phase. The trial did not establish this as a general dose for people without bipolar disorder or outside clinical research. (Research)

Result: Statistically significant improvement
Evidence strength: Limited
Notes / limitations: The studied context was adjunctive psychiatric research, not general self-directed use.

200 mg single oral dose:

A 200 mg oral methylene blue MMX dose was studied for colonoscopy visualization. In a phase 3 trial of adults aged 50–75 undergoing screening or surveillance colonoscopy, the 200 mg modified-release formulation increased adenoma detection rate compared with placebo. This formulation was designed for localized colon staining and should not be interpreted as equivalent to ordinary immediate-release oral exposure. EMA identifies Lumeblue as a diagnostic agent for enhancing visualization of colorectal lesions during colonoscopy. (Research) (EMA)

Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: This is a diagnostic medical context with a specific modified-release formulation.

260 mg single oral dose:

A 260 mg single oral exposure was studied after exposure sessions in fear-extinction research. In adults with marked claustrophobic fear, methylene blue was given after an exposure session to evaluate whether it influenced retention of extinction learning. The study reported improved extinction retention after successful exposure learning, but results depended on the quality of the exposure-session response. This does not support standalone use for anxiety or fear conditions. (Research)

Result: Statistically significant improvement
Evidence strength: Emerging
Notes / limitations: The dose was tied to structured exposure therapy and specific timing after learning.

300 mg/day:

A 300 mg/day oral exposure was studied in a two-year double-blind crossover trial in bipolar manic-depressive illness. Participants were maintained on lithium and spent one year at 15 mg/day and one year at 300 mg/day. Depressive symptoms were reported as less severe during the higher-dose year, while manic symptoms were not significantly different. The long duration is notable, but the population and design are specialized and do not establish a general dose. (Research)

Result: Mixed findings
Evidence strength: Limited
Notes / limitations: This was a psychiatric research context with clinical monitoring.

Weight-based intravenous critical-care exposures:

Intravenous methylene blue has been studied in septic shock and vasoplegic shock using weight-based dosing rather than fixed milligram dosing. One pilot septic shock RCT used a 2 mg/kg bolus followed by escalating infusions of 0.25, 0.5, 1, and 2 mg/kg/hour. Another registered severe sepsis and septic shock protocol specified 2 mg/kg followed by 0.5 mg/kg/hour for 6 hours. These exposures belong to ICU or protocolized medical settings and cannot be converted into a general fixed oral dose. (Research) (Research)

Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: IV critical-care dosing is not comparable to oral consumer exposure.

Weight-based malaria-study exposures:

Malaria studies used weight-based oral methylene blue exposures in combination regimens. A pediatric trial used 12 mg/kg total over 3 days, while a dose-finding study evaluated 36, 54, and 72 mg/kg total doses with chloroquine. A transmission-blocking trial used 15 mg/kg/day for 3 days in G6PD-normal, gametocytaemic participants. These studies support malaria research context only and also highlight tolerability and acceptability issues. (Research) (Research) (Research)

Result: Mixed findings
Evidence strength: Limited
Notes / limitations: These exposures are infection-research regimens and are not general supplement doses.

Key Takeaways from Human Research

• Methylene blue has regulated medical and diagnostic roles, including FDA-labeled acquired methemoglobinemia treatment and EMA-authorized colonoscopy visualization use. (FDA) (EMA)
• Cardiovascular Health evidence in septic shock and vasoplegia is clinically important but remains limited by heterogeneous trials, critical-care settings, and variable protocols. (Review) (Review)
• Cognitive Health studies show acute neuroimaging and memory-related signals, but small sample sizes and short durations prevent strong general conclusions. (Research) (Research)
• Mental Health research includes bipolar disorder and fear-extinction studies, but findings are adjunctive and not sufficient to define routine psychiatric use. (Research) (Research)
• Infection research has explored malaria combination therapy and transmission blocking, with evidence complicated by dose, combination regimens, acceptability, and formulation issues. (Review)
• Safety interpretation requires caution because FDA labeling warns about serotonin syndrome with serotonergic drugs and contraindications or cautions in specific populations. (FDA)

Origin & Natural Occurrence

Methylene blue is synthetic and does not have a normal dietary source. It was developed as a dye and later became medically important because of its redox chemistry and staining properties. (Review)

The compound is used in different forms depending on the setting, including injectable methylene blue for acquired methemoglobinemia and modified-release oral methylthioninium chloride for colonoscopy visualization. (FDA) (EMA)

Manufacturing origin matters because formulation, purity, route, and release pattern affect interpretation. A colon-targeted MMX tablet used for diagnostic staining is not the same exposure context as immediate-release oral liquid, oral psychiatric research dosing, or intravenous critical-care use. (Research) (Research) (FDA)

How It Behaves in the Body

In plain language, methylene blue can move between oxidized and reduced forms, which allows it to help transfer electrons in certain biological reactions. This redox cycling is one reason it has been studied in blood chemistry, mitochondrial biology, and vasodilatory shock. (Review) (Review)

In acquired methemoglobinemia, FDA labeling describes methylene blue as a water-soluble thiazine dye that promotes conversion of methemoglobin back toward hemoglobin. The label explains that methylene blue is converted to leucomethylene blue, which then reduces the ferric iron of methemoglobin to the ferrous state of normal hemoglobin. (FDA)

In vasodilatory shock research, methylene blue has been studied because it can influence nitric-oxide-related signaling involved in blood-vessel relaxation. Human septic shock and vasoplegia studies evaluate whether this mechanism can support blood pressure and reduce vasopressor requirements in monitored critical-care settings. (Research) (Review)

In neuropsychiatric research, reviews discuss mitochondrial and redox mechanisms as possible explanations for observed effects in small human studies. These mechanisms remain more established as biological plausibility than as proof of broad clinical benefit. (Review) (Research)

Human pharmacokinetic studies show that oral methylene blue can be absorbed and that route of administration affects distribution. A human study reported high absolute bioavailability for an aqueous oral formulation, while other pharmacokinetic research evaluated absorption, metabolism, excretion, and route-dependent distribution. (Research) (Research) (Research)

FDA labeling for IV methylene blue reports an approximate human half-life of 24 hours, approximately 94% in vitro plasma protein binding, and about 40% urinary excretion as unchanged methylene blue. (FDA) These values are useful pharmacology anchors, but they should not be treated as universal across oral liquids, colon-targeted tablets, IV treatment, and disease states. (Research) (Research)

Absorption & Delivery Formats

Oral immediate-release: Oral methylene blue has been used in psychiatric, fear-extinction, malaria, and pharmacokinetic studies. A human pharmacokinetic study reported high absolute bioavailability for an aqueous oral formulation, but this does not make all oral formulations equivalent. (Research)

Oral extended-release: Modified-release methylene blue MMX has been studied for colonoscopy visualization. MMX refers to a tablet technology designed to release methylene blue throughout the colon for staining during colonoscopy, not a standard immediate-release oral drop or capsule exposure. (Research) (Research)

Sublingual: The reviewed human evidence does not include trials specifically validating sublingual methylene blue exposure. Because methylene blue has pharmacological and interaction risks, lack of sublingual evidence should not be interpreted as evidence of safety. (FDA)

Transdermal: The reviewed human evidence does not include transdermal methylene blue studies suitable for supporting efficacy or pharmacokinetic claims. Any transdermal discussion should therefore be described as unsupported by the reviewed human evidence. (Review)

Injectable / IV: Intravenous methylene blue appears in FDA labeling for acquired methemoglobinemia and in critical-care research on septic shock and vasoplegia. FDA labeling describes IV administration at 1 mg/kg over 5–30 minutes for acquired methemoglobinemia, with a possible repeat dose in specified medical circumstances. (FDA) (Research)

Quick Facts at a Glance

I double-checked the Quick Facts at a Glance section. The main mix-up is indeed Typical duration. Most other entries are directionally fine, but a few should be tightened so they do not blur PK facts, study design, and clinical context.

Here is the cleaner version I’d use for that whole section:

Quick Facts at a Glance

Onset (reported): Acute neuroimaging research measured brain activity and memory-related outcomes about 1 hour after oral administration. FDA labeling for acquired methemoglobinemia reports that the first post-dose methemoglobin assessment occurred from 0.2 to 27.3 hours after the first infusion ended, with a median of 2.7 hours. (Research) (FDA)

Time to peak (Tmax): A single universal Tmax should not be stated because the reviewed evidence includes aqueous oral formulations, IV infusion, and colon-targeted MMX tablets. For IV PROVAYBLUE, FDA labeling reports exposure after a 2 mg/kg dose administered as a 5-minute IV infusion, while MMX tablets are designed for delayed colonic delivery rather than rapid systemic exposure. (FDA) (Research)

Half-life (t½): FDA labeling reports that methylene blue has a human half-life of approximately 24 hours. The same label notes that renal impairment increased AUC after a 1 mg/kg dose, with AUC increases of 52%, 116%, and 192% in mild, moderate, and severe renal impairment, respectively. (FDA)

Typical duration: Methylene blue does not have one universal duration of action because route and formulation change the exposure pattern. In FDA labeling, IV methylene blue has an approximate half-life of 24 hours, and clinical methemoglobin reassessment occurred from 0.2 to 27.3 hours after infusion, with a median of 2.7 hours. Oral neuroimaging research assessed acute effects at about 1 hour, while MMX colonoscopy tablets are designed for procedure-specific colonic staining rather than a general systemic effect window. (FDA) (Research) (Research)

Absorption routes studied: Oral and intravenous routes are the main human routes in the reviewed evidence. Oral evidence includes aqueous oral pharmacokinetic work and MMX modified-release tablets, while IV evidence includes FDA-labeled acquired methemoglobinemia treatment and critical-care shock research. (Research) (Research) (FDA)

Formulation differences: Formulation is a major interpretation driver. FDA-labeled injection is supplied as 5 mg/mL, oral MMX studies used 100 mg and 200 mg colon-targeted tablets, and psychiatric studies used daily oral exposures such as 15 mg/day, 195 mg/day, and 300 mg/day. (FDA) (Research) (Research) (Research)

Variability drivers: Variability may arise from route, formulation, clinical condition, concurrent medications, G6PD status, renal function, and hepatic function. FDA labeling reports that methylene blue is approximately 94% protein bound in vitro, that about 40% is excreted unchanged in urine, and that renal impairment can substantially increase exposure. (FDA)

Tolerance / adaptation: The reviewed evidence does not establish a clear tolerance or adaptation pattern for general methylene blue exposure. Longer psychiatric studies exist, including a 2-year bipolar crossover trial, but they do not define tolerance in the way stimulant, sedative, or dependence-forming compounds are often discussed. (Research)

Evidence strength snapshot: Evidence is strongest for regulated medical or diagnostic contexts and weaker for broad Cognitive Health or Mental Health claims. Numerically, the human evidence includes small neuroimaging studies, a 37-person bipolar crossover study, a 31-person bipolar crossover trial, a 20-person septic shock pilot RCT, and larger colonoscopy research with a reported 8.5% absolute increase in adenoma detection rate for methylene blue MMX. (Research) (Research) (Research) (Research) (Research)

Other Physiological Contexts Studied (If Applicable)

• Methylene blue has been reviewed for ifosfamide-induced encephalopathy, but evidence was reported to consist mainly of case reports and retrospective data, which limits confidence. (Review)
• Human pharmacokinetic studies have evaluated oral absorption, metabolism, excretion, and distribution, which helps distinguish route-specific exposure from broad ingredient claims. (Research) (Research) (Research)
• FDA clinical pharmacology materials support labeling-related pharmacology for the approved injectable product, but those materials apply to drug review rather than consumer ingredient use. (FDA)
• A colonoscopy safety study evaluated DNA damage in colonic mucosa after oral methylene blue MMX exposure, reflecting formulation-specific safety assessment in a diagnostic setting. (Research)

Safety, Interactions & Regulation

Methylene blue safety cannot be summarized by dose alone because risk depends on route, formulation, indication, medications, G6PD status, renal function, hepatic function, and clinical monitoring. FDA labeling includes warnings and contraindications that make general self-directed dosing language inappropriate. (FDA)

Adverse effects: FDA labeling reports common adverse reactions above 2%, including headache, hypokalemia, diarrhea, hypomagnesemia, myoclonus, nausea, and seizure-like phenomena. (FDA) Human malaria studies also reported visible discoloration and tolerability or acceptability issues, including vomiting in dose-finding work. (Research)

Interaction categories: FDA labeling warns that methylene blue can cause serious or fatal serotonin syndrome when used with serotonergic drugs and opioids. (FDA) DailyMed labeling also highlights serotonin-syndrome risk with serotonergic medications. (FDA)

Population cautions: FDA labeling lists G6PD deficiency as a contraindication because of hemolytic-anemia risk. (FDA) The label also includes cautions for pregnancy, lactation, renal impairment, hepatic impairment, and monitoring interference. (FDA)

U.S. regulatory status: In the United States, PROVAYBLUE is an FDA-labeled methylene blue injection for acquired methemoglobinemia. (FDA) The FDA label describes prescription drug use and does not establish methylene blue as a dietary supplement ingredient with a general wellness dose. (FDA)

EU regulatory status: In the European Union, EMA identifies Lumeblue as a methylthioninium chloride medicinal product used to enhance visualization of colorectal lesions during screening or surveillance colonoscopy. (EMA) EMA product information states Lumeblue is prescription-only and used as a blue dye to temporarily stain the colon before colonoscopy. (EMA)

Evidence Overview

The human evidence base for methylene blue is strongest in regulated medical and diagnostic contexts and more limited for broad ingredient-style claims. FDA labeling supports its medical role in acquired methemoglobinemia, EMA authorization supports methylthioninium chloride MMX as a colonoscopy visualization dye, and systematic reviews describe active but still limited research in septic shock and vasodilatory shock. (FDA) (EMA) (Review) Evidence is weaker for Cognitive Health and Mental Health because studies are generally small, short-term, adjunctive, or specialized. (Research) (Research) Confidence is not higher because the literature combines very different routes, formulations, populations, outcomes, and clinical settings. (Review)

Cardiovascular Health research is clinically important because methylene blue has been studied in septic shock and vasoplegic syndrome, where nitric-oxide-related vasodilation contributes to low vascular tone. Randomized trials and meta-analyses report potential improvements in vasopressor-related outcomes and possibly short-term clinical outcomes, but systematic reviews still emphasize imprecision, heterogeneity, and risk of bias. (Research) (Review) (Review)

Digestive and Gastrointestinal Health evidence is relatively specific because methylene blue MMX was designed as a colon-targeted diagnostic dye. A phase 3 colonoscopy trial reported an 8.5% absolute increase in adenoma detection, and EMA authorization supports this diagnostic use in adults undergoing screening or surveillance colonoscopy. (Research) (EMA)

Infection evidence is centered on malaria rather than broad antimicrobial use. Human studies show antimalarial and transmission-blocking interest, but dose, combination regimen, formulation, population, and tolerability issues shape interpretation. (Review) (Research)

Neuropsychiatric research is mechanistically interesting but less mature. Small neuroimaging trials, bipolar disorder studies, and fear-extinction trials suggest measurable human effects, but these findings remain far from proving generalized cognitive enhancement or psychiatric benefit. (Research) (Research) (Review)

Evidence Confidence Classification

Limited / Mixed is the overall human evidence classification for methylene blue as an ingredient-style substance, because strong regulated medical and diagnostic uses coexist with small, heterogeneous, and context-specific research in cognition, mood, infection, and critical care. (FDA) (EMA) (Review)

The classification is not “Strong” for general use because much of the strongest evidence applies to prescription, diagnostic, or critical-care settings rather than everyday oral exposure. (FDA) (Research) (Review)

Mechanistic plausibility is substantial, especially around redox biology, mitochondrial mechanisms, and nitric-oxide-related vascular signaling, but mechanistic plausibility does not replace large, consistent human outcome trials. (Review) (Review)

The evidence is best summarized as strong for certain regulated contexts, moderate-to-limited for specific clinical research areas, and emerging or insufficient for broad consumer-style Cognitive Health or Mental Health claims. (FDA) (Research) (Research)

Similar Ingredients & Comparators

Similar supplement-style ingredients:

• Nicotinamide riboside
• NMN
• CoQ10
• Alpha-lipoic acid
• Riboflavin
• Creatine
• Acetyl-L-carnitine
• PQQ
• N-acetylcysteine
• Melatonin

Medical / pharma comparator categories:

• Methemoglobinemia treatments
• Vasopressors and shock-support agents
• Diagnostic contrast and staining agents
• Antimalarial combination therapies
• Psychiatric adjunctive agents
• Mitochondrial-targeted investigational agents

Combination Context

Methylene Blue + Chloroquine:

This combination was studied in children with uncomplicated falciparum malaria. The randomized trial found the combination was generally tolerated but not sufficiently effective at the studied methylene blue dose in that setting. (Research)

Methylene Blue + Chloroquine in Dose-Finding Research:

A dose-finding study evaluated escalating methylene blue doses combined with chloroquine in young children with uncomplicated falciparum malaria. The study helped characterize tolerability, vomiting, discoloration, and acceptability issues rather than establishing broad use. (Research)

Methylene Blue + Lamotrigine:

Adjunctive methylene blue was studied in people with bipolar disorder already receiving lamotrigine. The crossover trial reported improvement in residual depressive and anxiety symptoms during the higher-dose methylene blue phase, but the population and design limit general interpretation. (Research)

Methylene Blue + Lithium:

A two-year crossover trial studied methylene blue in bipolar manic-depressive subjects maintained on lithium. Depressive symptoms were less severe during the higher-dose year, while manic symptoms were not significantly different. (Research)

Methylene Blue + Vasopressor Support:

Critical-care studies have examined methylene blue as an adjunct to vasopressor support in septic shock and vasoplegic states. This combination context belongs to monitored medical care and cannot be generalized to oral ingredient use. (Research) (Review)

FAQ

What is methylene blue?

Methylene blue is a synthetic redox-active thiazine dye and medical compound also known as methylthioninium chloride. (Review) It is used or studied in medical, diagnostic, infectious-disease, critical-care, and neuropsychiatric contexts. (FDA) (EMA) It is not a natural dietary nutrient and should not be described like a conventional food-derived supplement. (Review)

What does human research study it for?

Human research studies methylene blue for Blood Health, Cardiovascular Health, Digestive and Gastrointestinal Health, Infection, Cognitive Health, and Mental Health. (FDA) (Review) (Research) (Review) (Review) The strongest contexts are medical or diagnostic rather than consumer wellness contexts. (FDA) (EMA)

What are the best-supported uses?

The best-supported uses are regulated or clinical contexts, especially FDA-labeled acquired methemoglobinemia treatment and EMA-authorized colonoscopy visualization. (FDA) (EMA) Cardiovascular Health research in septic shock and vasoplegia is also clinically important, but systematic reviews still describe limitations in certainty. (Review) (Review)

Where is evidence mixed or limited?

Evidence is mixed or limited for Cognitive Health and Mental Health because trials are generally small, short-term, adjunctive, or specialized. (Research) (Research) Infection evidence is also context-specific because malaria studies used combination regimens and highlighted formulation and tolerability issues. (Review)

How quickly does it act?

Reported timing depends on route and study context. In Cognitive Health research, acute neuroimaging outcomes were measured about 1 hour after oral administration. (Research) In FDA-reviewed acquired methemoglobinemia evidence, the first post-dose methemoglobin assessment occurred from 0.2 to 27.3 hours after the first infusion ended, with a median of 2.7 hours. (FDA)

What affects absorption and variability?

Absorption and variability are affected by route, formulation, clinical context, and individual risk factors. (Research) Aqueous oral formulations, colon-targeted MMX tablets, and IV drug products should not be treated as interchangeable. (Research) (FDA) FDA labeling reports approximately 24 hours half-life, about 40% urinary excretion unchanged, and exposure increases in renal impairment. (FDA)

Is tolerance reported?

A general tolerance pattern is not established for methylene blue. Longer psychiatric studies exist, including a 2-year bipolar crossover trial, but they do not define tolerance or adaptation for general oral use. (Research) Because methylene blue is pharmacologically active and regulated in several contexts, tolerance should not be assumed from absence of evidence. (FDA)

Why do studies disagree?

Studies disagree because they use different routes, formulations, populations, doses, outcomes, and clinical settings. (Review) A 200 mg MMX colonoscopy dye study cannot be interpreted the same way as an IV septic shock trial or an acute oral neuroimaging study. (Research) (Research) (Research) These differences explain why methylene blue has stronger evidence in some medical contexts and weaker evidence for broad wellness claims. (Review)

What ingredients is it commonly combined with and why?

In human research, methylene blue has been combined with chloroquine in malaria studies, lamotrigine or lithium in bipolar disorder studies, and vasopressor support in critical-care research. (Research) (Research) (Research) (Research) These combinations were studied for specific research or medical reasons rather than as general wellness stacks. (Review) (Review)

What foods naturally contain this ingredient?

No ordinary food source for methylene blue is identified in the reviewed human evidence. Methylene blue is synthetic and is better described as a dye, drug, and research compound than as a dietary ingredient. (Review) Because it is not a nutrient, dietary intake bands do not apply. (FDA)

How is it regulated?

In the United States, methylene blue injection is FDA-labeled for acquired methemoglobinemia. (FDA) FDA labeling includes major warnings, including serotonin-syndrome risk with serotonergic drugs. (FDA) In the European Union, EMA identifies Lumeblue as a prescription diagnostic product for enhancing visualization of colorectal lesions during colonoscopy. (EMA)

Resources

Methylene Blue Injection Label — FDA — https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204630s021lbl.pdf

DailyMed Methylene Blue Label — FDA / DailyMed — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2d9d96c-a711-47c5-855a-7eb7f163493e

Lumeblue EPAR — EMA — https://www.ema.europa.eu/en/medicines/human/EPAR/lumeblue

Lumeblue Product Information — EMA — https://www.ema.europa.eu/en/documents/product-information/lumeblue-epar-product-information_en.pdf

Methylene Blue and Neuropsychiatric Disorders — CNS Drugs Review — https://pubmed.ncbi.nlm.nih.gov/31144270/

Methylene Blue in Septic Shock Meta-Analysis — Systematic Review — https://pubmed.ncbi.nlm.nih.gov/38904978/

Methylene Blue MMX Phase 3 Colonoscopy Trial — Research — https://pubmed.ncbi.nlm.nih.gov/30742834/

Methylene Blue Cognitive fMRI Study — Research — https://pubmed.ncbi.nlm.nih.gov/27351678/

Methylene Blue Bipolar Disorder Trial — Research — https://pubmed.ncbi.nlm.nih.gov/27284082/

Methylene Blue Malaria Review — Systematic Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC5979000/

More from the Supplement Ingredients & Medical Ingredients Encyclopedia​